Michael Dal Molin
Overview
Explore the profile of Michael Dal Molin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
153
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Dal Molin M, Selchow P, Schafle D, Tschumi A, Ryckmans T, Laage-Witt S, et al.
J Mol Med (Berl)
. 2019 Nov;
97(11):1601-1613.
PMID: 31728550
Drug resistance in Mycobacterium tuberculosis is relentlessly progressing while only a handful of novel drug candidates are developed. Here we describe a GFP-based high-throughput screening of 386,496 diverse compounds to...
12.
Hohl M, Remm S, Eskandarian H, Dal Molin M, Arnold F, Hurlimann L, et al.
Mol Microbiol
. 2019 Feb;
111(5):1263-1282.
PMID: 30742339
The major facilitator superfamily transporter Rv1410 and the lipoprotein LprG (Rv1411) are encoded by a conserved two-gene operon and contribute to virulence in Mycobacterium tuberculosis. Rv1410 was originally postulated to...
13.
Becker K, Haldimann K, Selchow P, Reinau L, Dal Molin M, Sander P
Front Microbiol
. 2017 Nov;
8:2123.
PMID: 29163413
Lipoproteins are important components of the mycobacterial cell envelope due to their function in cell wall homeostasis and bacterial virulence. They are post-translationally modified with lipid- and glycosyl-residues in various...
14.
Dal Molin M, Gut M, Rominski A, Haldimann K, Becker K, Sander P
Antimicrob Agents Chemother
. 2017 Oct;
62(1).
PMID: 29061744
Streptomycin, the first drug used for the treatment of tuberculosis, shows limited activity against the highly resistant pathogen We recently identified two aminoglycoside-acetylating genes [ and ] which, however, do...
15.
Rominski A, Selchow P, Becker K, Brulle J, Dal Molin M, Sander P
J Antimicrob Chemother
. 2017 May;
72(8):2191-2200.
PMID: 28486671
Objectives: Mycobacterium abscessus is innately resistant to a variety of drugs thereby limiting therapeutic options. Bacterial resistance to aminoglycosides (AGs) is conferred mainly by AG-modifying enzymes, which often have overlapping...
16.
Sander P, Becker K, Dal Molin M
Cell Chem Biol
. 2016 Sep;
23(9):1044-1046.
PMID: 27662250
Mycobacterium tuberculosis synthesizes a wide variety of complex lipids that can serve as antigens in immune recognition of the bacterium. In this issue of Cell Chemical Biology, Gilleron et al....
17.
Mohanty S, Dal Molin M, Ganguli G, Padhi A, Jena P, Selchow P, et al.
Tuberculosis (Edinb)
. 2016 Jan;
96:44-57.
PMID: 26786654
Mycobacterium tuberculosis (Mtb) survives inside the macrophages by modulating the host immune responses in its favor. The 6-kDa early secretory antigenic target (ESAT-6; esxA) of Mtb is known as a...
18.
Sander P, Clark S, Petrera A, Vilaplana C, Meuli M, Selchow P, et al.
Vaccine
. 2015 Feb;
33(11):1353-9.
PMID: 25657094
Having demonstrated previously that deletion of zinc metalloprotease zmp1 in Mycobacterium bovis BCG increased immunogenicity of BCG vaccines, we here investigated the protective efficacy of BCG zmp1 deletion mutants in...